A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Recruiting · NCT06850038
Conditions: Alagille Syndrome
At a glance
- Research payments reported, 2025
- $48,214
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Ipsen
- Dates
- Started 2025-04-22; completion 2030-11-30
- Results posted
- Not yet
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Pharma Sas reported $48,214 in research payments for this study in 2025 (12 payments).
Products named: Bylvay
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rohit Kohli, MBBS, MS Pediatric Gastroenterology · Los Angeles, CA
- Nadia Ovchinsky Pediatric Gastroenterology · New York, NY
- John K. Eshun, MD Pediatric Gastroenterology · Memphis, TN
- Eduardo D. Rosas Blum, M.D. Pediatric Gastroenterology · El Paso, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- NYU Post - Graduate Med School $19,643
- Le Bonheur Childrens Hospital $16,000
- Children's Hosp of Los Angeles, CA $8,550
- Proactive Clinical Research $2,076
- New York University School of Medicine $1,945
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.